Literature DB >> 3534002

Prevention of lethal murine graft versus host disease by treatment of donor cells with L-leucyl-L-leucine methyl ester.

M Charley, D L Thiele, M Bennett, P E Lipsky.   

Abstract

Graft vs. host disease (GVHD) remains one of the main problems associated with bone marrow transplantation. The current studies were undertaken to determine whether treatment of the donor inoculum with the anticytotoxic cell compound L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) would alter the development of GVHD in a murine model. Irradiated recipient mice transplanted with a mixture of control bone marrow and spleen cells from naive semiallogeneic donors died rapidly from GVHD, whereas the recipients of cells incubated with 250 microM Leu-Leu-OMe all survived. In addition, Leu-Leu-OMe treatment of cells obtained from donors immunized against host alloantigens resulted in significantly prolonged survival. Phenotypic characterization of spleen cells from the various groups of mice that had received Leu-Leu-OMe-treated cells and survived consistently revealed the donor phenotype. Treatment of marrow cells with 250 microM Leu-Leu-OMe appeared to have no adverse effects on stem cell function. Erythropoiesis was undiminished, as assayed by splenic 5-iodo-2'-deoxyuridine-125I uptake. Moreover, granulocytic and megakaryocytic regeneration were histologically equivalent in the spleens of recipients of control or Leu-Leu-OMe-treated cells. Treatment of the donor inoculum with Leu-Leu-OMe thus prevents GVHD in this murine strain combination with no apparent stem cell toxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534002      PMCID: PMC423850          DOI: 10.1172/JCI112730

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Hemopoietic progenitor cells of W anemic mice studies in vivo and in vitro.

Authors:  M Bennett; G Cudkowicz; R S Foster; D Metcalf
Journal:  J Cell Physiol       Date:  1968-06       Impact factor: 6.384

2.  Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex.

Authors:  K Ozato; T H Hansen; D H Sachs
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

3.  Bone marrow transplantation across major histocompatability barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants.

Authors:  D A Vallera; C C Soderling; J H Kersey
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

4.  Failure of a pan-reactive anti-T cell antibody, OKT 3, to prevent graft versus host disease in severe combined immunodeficiency.

Authors:  A R Hayward; S Murphy; J Githens; G Troup; D Ambruso
Journal:  J Pediatr       Date:  1982-04       Impact factor: 4.406

5.  Attempts at standardization of lupus-like graft-vs-host disease: inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice.

Authors:  F M Van Rappard-Van Der Veen; T Radaszkiewicz; L Terraneo; E Gleichmann
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

6.  Clonal analysis of murine graft-vs-host disease. II. Leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs. host disease.

Authors:  Y DeClerck; V Draper; R Parkman
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

7.  Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.

Authors:  K Ozato; D H Sachs
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

8.  Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1.

Authors:  M R Charley; A Mikhael; M Bennett; J N Gilliam; R D Sontheimer
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

9.  Autologous marrow recovery and sensitization to non-HLA antigens after HLA-identical marrow transplantation for aplastic anemia.

Authors:  M S Tsoi; R P Warren; R Storb; R P Witherspoon; E Mickelson; E R Giblett; M S Schanfield; P Weiden; E D Thomas
Journal:  Exp Hematol       Date:  1983-01       Impact factor: 3.084

10.  Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.

Authors:  R Korngold; J Sprent
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  5 in total

1.  A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway.

Authors:  Fabio Rabelo Melo; Ida Waern; Elin Rönnberg; Magnus Åbrink; David M Lee; Susan M Schlenner; Thorsten B Feyerabend; Hans-Reimer Rodewald; Boris Turk; Sara Wernersson; Gunnar Pejler
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

2.  Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells.

Authors:  D L Thiele; P E Lipsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes.

Authors:  D L Thiele; M L Eigenbrodt; S E Bryde; E H Eigenbrodt; P E Lipsky
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  Generalized toxicity of L-leucyl-leucine-methyl ester for lymphocyte functions.

Authors:  A M Mowat; P A Leck
Journal:  Immunology       Date:  1990-04       Impact factor: 7.397

5.  The lysosomotropic drug LeuLeu-OMe induces lysosome disruption and autophagy-independent cell death in Trypanosoma brucei.

Authors:  Hazel X Koh; Htay M Aye; Kevin S W Tan; Cynthia Y He
Journal:  Microb Cell       Date:  2015-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.